Catalent (CTLT) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Catalent Revenue Highlights


Latest Revenue (Y)

$4.38B

Latest Revenue (Q)

$1.02B

Main Segment (Y)

PharmaConsumerHealth

Main Geography (Y)

UNITED STATES

Catalent Revenue by Period


Catalent Revenue by Year

DateRevenueChange
2024-06-30$4.38B2.46%
2023-06-30$4.28B-11.43%
2022-06-30$4.83B20.76%
2021-06-30$4.00B29.21%
2020-06-30$3.09B22.89%
2019-06-30$2.52B2.22%
2018-06-30$2.46B18.70%
2017-06-30$2.08B12.30%
2016-06-30$1.85B0.94%
2015-06-30$1.83B0.17%
2014-06-30$1.83B1.52%
2013-06-30$1.80B6.22%
2012-06-30$1.69B10.64%
2011-06-30$1.53B-

Catalent generated $4.38B in revenue during NA 2024, up 2.46% compared to the previous quarter, and up 173.99% compared to the same period a year ago.

Catalent Revenue by Quarter

DateRevenueChange
2024-09-30$1.02B-21.37%
2024-06-30$1.30B21.14%
2024-03-31$1.07B4.88%
2023-12-31$1.02B4.28%
2023-09-30$982.00M-8.05%
2023-06-30$1.07B2.99%
2023-03-31$1.04B-9.75%
2022-12-31$1.15B12.43%
2022-09-30$1.02B-22.16%
2022-06-30$1.31B3.14%
2022-03-31$1.27B4.60%
2021-12-31$1.22B18.73%
2021-09-30$1.02B-13.72%
2021-06-30$1.19B12.79%
2021-03-31$1.05B15.65%
2020-12-31$910.80M7.70%
2020-09-30$845.70M-10.75%
2020-06-30$947.60M24.59%
2020-03-31$760.60M5.43%
2019-12-31$721.40M8.53%
2019-09-30$664.70M-8.41%
2019-06-30$725.70M17.52%
2019-03-31$617.50M-0.88%
2018-12-31$623.00M12.90%
2018-09-30$551.80M-19.48%
2018-06-30$685.30M9.14%
2018-03-31$627.90M3.56%
2017-12-31$606.30M11.47%
2017-09-30$543.90M-11.83%
2017-06-30$616.90M15.83%
2017-03-31$532.60M10.11%
2016-12-31$483.70M9.38%
2016-09-30$442.20M-16.91%
2016-06-30$532.20M21.51%
2016-03-31$438.00M-3.72%
2015-12-31$454.90M7.54%
2015-09-30$423.00M-17.08%
2015-06-30$510.10M14.22%
2015-03-31$446.60M-2.02%
2014-12-31$455.80M8.96%
2014-09-30$418.30M-19.50%
2014-06-30$519.60M14.68%
2014-03-31$453.10M2.81%
2013-12-31$440.70M6.37%
2013-09-30$414.30M-17.99%
2013-06-30$505.20M13.02%
2013-03-31$447.00M2.50%
2012-12-31$436.10M5.85%
2012-09-30$412.00M-

Catalent generated $1.02B in revenue during Q1 2025, up -21.37% compared to the previous quarter, and up 95.79% compared to the same period a year ago.

Catalent Revenue Breakdown


Catalent Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceJun 24Jun 22Jun 21Jun 20Jun 19
PharmaConsumerHealth$2.43B----
Biologics$1.95B$2.55B$1.93B$1.02B-
Clinical Supply Services-$400.00M---
Softgel and Oral Technologies-$1.25B$1.01B$1.06B-
Oral and Specialty Delivery-$650.00M$686.00M$675.90M-
Softgel Technologies-$1.25B$872.10M--
Oral Drug Delivery-$650.00M$619.90M--
Total Catalent before inter-segment revenue elimination-$400.00M$4.02B$3.10B$2.56B
Biologics and Specialty Drug Delivery----$742.10M

Catalent's latest annual revenue breakdown by segment (product or service), as of Jun 24: PharmaConsumerHealth (55.46%), and Biologics (44.54%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Biologics$461.00M$605.00M$461.00M$438.00M$448.00M$475.00M$580.00M$523.00M$667.00M$698.00M$638.00M$546.00M$603.30M$543.70M$403.90M-----
PharmaConsumerHealth$563.00M$697.00M$613.00M-----------------
Total Catalent before inter-segment revenue elimination--$663.00M$651.00M$616.00M$1.04B$1.15B$1.02B$1.31B$1.28B$1.22B$1.03B$1.19B$1.06B$913.90M$849.20M$951.30M$762.60M$724.20M$669.50M
Clinical Supply Services--------$104.00M---$104.80M---$83.60M---
Softgel Technologies---------$324.00M$329.00M$243.00M$243.70M$246.60M$221.10M$242.30M$267.90M$263.70M--
Oral Drug Delivery---------$154.00M$156.00M$146.00M$171.70M$169.90M$158.30M$181.40M$143.20M$132.60M--
Biologics and Specialty Drug Delivery---------------$377.10M$250.00M$225.20M$188.60M-

Catalent's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: PharmaConsumerHealth (54.98%), and Biologics (45.02%).

Catalent Revenue Breakdown by Country

Annual Revenue by Country

CountryJun 24Jun 22Jun 21Jun 20Jun 19
Europe$1.36B$1.51B$1.34B$976.10M$842.10M
UNITED STATES$2.82B$3.11B$2.46B--
Softgel and Oral Technologies-$1.25B---
Oral and Specialty Delivery-$650.00M---
Clinical Supply Services-----
Biologics-$2.55B---
Total Catalent before inter-segment revenue elimination-$4.84B---
North America---$1.82B$1.32B

Catalent's latest annual revenue breakdown by geography, as of Jun 24: UNITED STATES (67.50%), and Europe (32.50%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
North America$658.00M$690.00M$653.00M$645.00M$685.00M$734.00M$697.00M$847.00M$793.00M$630.00M$670.00M$535.30M$516.90M$606.30M$438.90M$414.70M$362.30M---
Europe$331.00M$416.00M$345.00M$324.00M$274.00M$306.00M$356.00M$274.00M$411.00M$373.00M$370.00M$351.00M$388.20M$344.90M$326.40M$281.40M$286.00M$258.70M$221.40M$210.10M
Total Catalent before inter-segment revenue elimination------$1.15B-------------
Biologics------$580.00M-------------

Catalent's latest quarterly revenue breakdown by geography, as of Sep 24: North America (66.53%), and Europe (33.47%).

Catalent Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BIOBio-Rad Laboratories$2.67T$649.73M
IQVIQVIA$14.98B$3.90B
CTLTCatalent$4.38B$1.02B
CRLCharles River Laboratories$4.13B$1.03B
TFXTeleflex$2.97B$764.38M
WSTWest Pharmaceutical Services$2.95B$746.90M

CTLT Revenue FAQ


What is Catalent’s yearly revenue?

Catalent's yearly revenue for 2024 was $4.38B, representing an increase of 2.46% compared to 2023. The company's yearly revenue for 2023 was $4.28B, representing a decrease of -11.43% compared to 2022. CTLT's yearly revenue for 2022 was $4.83B, representing an increase of 20.76% compared to 2021.

What is Catalent’s quarterly revenue?

Catalent's quarterly revenue for Q1 2025 was $1.02B, a -21.37% decrease from the previous quarter (Q4 2024), and a 4.18% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $1.3B, a 21.14% increase from the previous quarter (Q3 2024), and a 21.82% increase year-over-year (Q4 2023). CTLT's quarterly revenue for Q3 2024 was $1.07B, a 4.88% increase from the previous quarter (Q2 2024), and a 3.57% increase year-over-year (Q3 2023).

What is Catalent’s revenue growth rate?

Catalent's revenue growth rate for the last 3 years (2022-2024) was -9.26%, and for the last 5 years (2020-2024) was 41.58%.

What are Catalent’s revenue streams?

Catalent's revenue streams in n 24 are PharmaConsumerHealth, and Biologics. PharmaConsumerHealth generated $2.43B in revenue, accounting 55.46% of the company's total revenue Biologics generated $1.95B in revenue, accounting 44.54% of the company's total revenue, down -23.42% year-over-year.

What is Catalent’s main source of revenue?

For the fiscal year ending Jun 24, the largest source of revenue of Catalent was PharmaConsumerHealth. This segment made a revenue of $2.43B, representing 55.46% of the company's total revenue.